Introduction
============

One common neurodegenerative disease, Parkinson's disease, has been linked to exposure to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and to inhaled manganese ^[@ref-1],\ [@ref-2]^. Similarly, inhaled aluminum dust has been associated with neurotoxic effects and pre-clinical cognitive impairment ^[@ref-3]^. Certain inhalation anesthetics have also been implicated in elevating AD risk, possibly by exacerbating the neurotoxic oligomerization of the amyloid-β (Aβ) peptide ^[@ref-4]^. The early involvement of the olfactory cortex in AD has caused longtime speculation that some inhaled agent might play a role in AD risk ^[@ref-5]^.

Recently, AD pathology was identified in young people living in areas with high levels of air pollution ^[@ref-6],\ [@ref-7]^. Furthermore, impaired cognition has been recently attributed to air pollution exposure in some populations ^[@ref-8]^. These converging lines of evidence led us to analyze brain levels of Aβ40 and Aβ42 in mice exposed to an inhaled particulate matter (nickel nanoparticle; Ni NP) model of air pollution.

Methods
=======

All procedures involving animals were conducted in compliance with guidelines for ethical animal research and approved by the New York University School of Medicine Animal Care and Use Committee. Two-month-old male and female FVBN mice (Taconic Farm, Hudson, NY) were randomly assigned to Ni NP inhalation (count median diameter 54 nm, at 1 mg/m ^3^, which is the current Occupational Safety and Health Administration's Permissible Exposure Limit for nickel hydroxide \[ <http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=standards&p_id=9992>\]) ( *n* = 16 per group) or control filtered air ( *n* = 5 per group) for 3 hours in a nose-only exposure chamber. This protocol has been established as a model for air pollution toxicity in pulmonary disease ^[@ref-9]^, atherosclerosis ^[@ref-10]^, and insulin resistance ^[@ref-11]^. Twenty-four hours post exposure, mice were given pentobarbital, bled out via the vena cava, and then their brains were harvested, snap frozen and stored at -80ºC until assay. For measurement of endogenous mouse brain Aβ40 and Aβ42, we employed the Schmidt method ^[@ref-12]^ and human/rat Aβ 1--40/1--42 ELISA kits (Wako, Richmond, VA). Statistical analysis was performed via Mann-Whitney test. \#8 Ni NP is excluded from the analysis due to being more than 2 SD\'s away from mean or closest value.

Results
=======

Both endogenous Aβ40 and Aβ42 were elevated in the brains of mice following Ni NP exposure ( [Figure 1](#f1){ref-type="fig"}). Aβ40 was increased by 1.72-fold ( *P* = 0.0011, Mann-Whitney test), and Aβ42 was increased by 2.29-fold ( *P* = 0.0005, Mann-Whitney test). Aβ42/40 ratio was also increased in the Ni NP-exposed group compared to the filtered air control group (0.27 ± 0.01 and 0.21 ± 0.007, respectively; P = 0.0093, Mann-Whitney test). Both male and female mice responded similarly to Ni NP exposure (male *vs*. female for Aβ40 and Aβ42 levels; *P* \> 0.1, Mann-Whitney test).

![Exposure to air pollution increases amyloid-β (Aβ) levels in the mouse brain.\
Elevated endogenous mouse brain Aβ40 and Aβ42 in mice exposed to nickel nanoparticles (count median diameter 54 nm, at 1 mg/m ^3^) ( *n* = 16 per group) versus filtered air ( *n* = 5 per group) for 3 hours in a nose-only exposure chamber. Data presented as mean + SEM. \*\* *P* \< 0.01, \*\*\* *P* \< 0.001 (Mann-Whitney test).](f1000research-1-450-g0000){#f1}

###### Raw data table for endogenous mouse brain Aβ40 and Aβ42 levels in mice exposed to nickel nanoparticles versus filtered air.

Raw data of endogenous mouse brain Aβ40 and Aβ42 levels (pmol/L) in mice exposed to nickel nanoparticles (count median diameter 54 nm, at 1 mg/m^3^) (n = 16 per group) versus filtered air (n = 5 per group) for 3 hours in a nose-only exposure chamber. \*Mouse 8 was excluded from the data analysis as these results were 2 SD\'s away from mean or closest value.

###### 

Click here for additional data file.

Discussion
==========

These data add credence to the proposal ^[@ref-4]^ that one or more inhaled neurotoxin(s) might increase the risk for AD by elevating levels of brain Aβ. We have not identified whether this accumulation occurs at the level(s) of transcription, translation, or post-translational processing. It is tempting to speculate that the well-known links between inhaled toxins and brain inflammation, and other links between brain inflammation and AD established by Griffin and colleagues ^[@ref-13]^ may underlie these phenomena.

The changes that we observed were dramatic, rapid, and unexpected. Human Aβ is more aggregatable than murine Aβ, making it conceivable that the effect on Aβ levels in human brain could be even greater. While elucidating the genesis and molecular underpinnings will be an important next step, an even more important step will be a rigorous application of environmental toxicology and epidemiology to determine whether the elevated brain Aβ caused in mice by this air pollution model corresponds to any situation of authentic human inhalation exposure that is linked to an increased risk for AD.
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This is an intriguing observation that might potentially have important relevance to the etiopathogenesis of Alzheimer's Disease.
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Linkage of environmental air toxicity from nanoparticles leading to Alzheimer-like changes in the brain of mice opens a new avenue to understanding the development of brain diseases. These findings are consistent with prior work showing particulate air pollution can affect the brains of human as well as dogs living in polluted cities.
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Neurodegenerative consequences are a looming possibility with the current increased burden of air-borne pollutants. Many studies have suggested an association between anesthesia administered to older adults and cognitive decline and development or progression of Alzheimer's disease (AD). A number of studies have already established links between air-borne pollutants and risk for development of systemic disorders several of which, like AD are inflammatory in nature. Gandy and his colleagues have taken a purposeful step toward more directly connecting air-pollution to increased risk for development of AD in a study of wild type mice exposed to a toxin at the OSHA permissible level for an 8h human exposure. The results are very convincing, showing that a one-time 3h exposure to nickel hydroxide nanoparticles at the "permissible" level doubled brain levels of Aβ40 and Aβ42 within 24h---increases that are similar to levels reported in younger adults with Down's syndrome. Interestingly, as noted by the authors, and in accord with systemic inflammatory consequences reported following exposure to air-borne pollutants, neuroinflammatory changes that drive Alzheimer neuropathological change may also be elicited by such exposure. This may be particularly important as we necessarily inhale air that appears to be "clean," but which contains permissible levels of agents that may have adverse effects on the brain, especially in persons with genetic risk factors and or co-morbid conditions that already predispose them for development of AD.
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